Abstract
Gliomas are the most common primary malignant brain tumors with invasion and metastasis. It is well recognized that gliomas are the most challenging diseases in the treatment of cancer. Traditional treatments such as surgical resection and chemotherapy/radiotherapy show poor efficacy. Fortunately, the molecular targeted therapy has been quickly developed and attracted people’s attention for its potential role in improving the prognosis of glioma patients. However, the molecular targeted therapy has limitations at present. It is important to explore more molecular targets and accomplish individualized treatment. Total exon sequencing has great advantages of high sequence coverage, sensitive capture rate and low price in the second generation sequencing techniques. It plays an important role in molecular targeted therapy by detecting key genomic mutations/molecular therapeutic targets and accomplishing individualized treatment. Taken together, the combination of total exon sequencing and molecular targeted therapy could achieve a greater benefit for the clinical treatment of gliomas. Key words: Glioma; Molecular mechanism; Molecular targeted therapy; Total exon sequencing
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have